Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL

Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL

Oxford, UK - 31 October 2017
: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis confirming submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Kymriah
^TM
(tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT). Kymriah
^TM
is a novel immunocellular therapy and a one-time treatment that uses a patient's own T cells to fight cancer.

The submission is based on results from the Novartis-sponsored, global, multi-centre Phase II JULIET study (NCT02445248), the first global, multi-centre registration study for Kymriah
^TM
in adult patients with r/r DLBCL. In April 2017, Novartis received Breakthrough Therapy designation for r/r DLBCL which, if approved, would be the second indication for Kymriah
^TM
.

Novartis plans to submit an additional application for marketing authorization for Kymriah
^TM
with the European Medicines Agency (EMA) in both DLBCL and paediatric ALL later this year. Novartis plans additional regulatory filings for Kymriah
^TM
outside the US and EU in 2018.

In August 2017, Kymriah
^TM
became the first available chimeric antigen receptor T cell (CAR-T) therapy when it received FDA approval five weeks prior to its PDUFA date and was launched for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL) that is refractory or has relapsed at least twice.

Oxford BioMedica is the sole manufacturer of the lentiviral vector that encodes Kymriah
^TM
. The Group signed an agreement with Novartis in July 2017 for the commercial and clinical supply of lentiviral vectors used to generate Kymriah
^TM
and other undisclosed CAR-T products, for which Oxford BioMedica could potentially receive in excess of $100m from Novartis over the next three years. As announced in October 2014, Oxford BioMedica will also receive undisclosed royalties on potential future sales of Novartis CAR-T products.

- Ends -

Notes for editors

About Oxford BioMedica


Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases.  Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector
^®
), which the Group leverages to develop
in vivo
and
ex vivo
products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.  Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at
www.oxfordbiomedica.co.uk
.